Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Istituto Giannina Gaslini
- Target Recruit Count
- 48
- Registration Number
- NCT05805930
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Jennifer Crombie, MD
- Target Recruit Count
- 41
- Registration Number
- NCT05800366
- Locations
- 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 30
- Registration Number
- NCT05777369
The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Jianhua Zhou
- Target Recruit Count
- 402
- Registration Number
- NCT05772871
- Locations
- 🇨🇳
Children's Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Anhui Children's Hospital, Hefei, Anhui, China
🇨🇳Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Conditions
- Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRefractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRecurrent Acute Leukemia of Ambiguous LineageRecurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRefractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-RearrangedRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous LineageRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: CytarabineDrug: Calaspargase PegolProcedure: EchocardiographyDrug: Fludarabine PhosphateDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateProcedure: Multigated Acquisition ScanDrug: PrednisoloneDrug: PrednisoneDrug: RevumenibDrug: Vincristine Sulfate
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 78
- Registration Number
- NCT05761171
- Locations
- 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT05689021
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- argenx
- Target Recruit Count
- 160
- Registration Number
- NCT05681481
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
🇨🇳Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
🇺🇸Medical Dermatology Specialists, Phoenix, Arizona, United States
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Target Recruit Count
- 200
- Registration Number
- NCT05678933
- Locations
- 🇨🇳
Tianjin Medical University Cancer Insititute & Hospital, Tianjin, Tianjin, China
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Conditions
- Interventions
- Procedure: Biospecimen CollectionBiological: Bleomycin SulfateProcedure: Computed TomographyDrug: Brentuximab VedotinDrug: DacarbazineDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingDrug: EtoposideProcedure: Positron Emission TomographyDrug: Etoposide PhosphateOther: Questionnaire AdministrationBiological: NivolumabDrug: Vinblastine SulfateRadiation: Involved-site Radiation TherapyDrug: PrednisoloneDrug: PrednisoneDrug: Procarbazine HydrochlorideDrug: Vincristine Sulfate
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1875
- Registration Number
- NCT05675410
- Locations
- 🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 52
- Registration Number
- NCT05673785
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
🇨🇳The First Affiliated Hospital of Zhejiang University school of medicine, Hangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.